Form 4: Prov3ctus Biopharma Exec Reports Stock Conversion

Edward Pershing, CEO and Director of Prov3ctus Biopharma, Inc., reported the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Prov3ctus Biopharma, Inc., filed a Form 4 statement detailing a transaction on April 4, 2026.
• The transaction involved the conversion of an 8% unsecured convertible promissory note into 33,977 shares of Series D-1 Convertible Preferred Stock.
• The conversion price for the note into Series D-1 Preferred Stock was $2.862 per share.
• The Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's Common Stock per share.
• The Series D-1 Convertible Preferred Stock is set to automatically convert into Common Stock on December 31, 2028, unless converted earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports a standard transaction of debt conversion into equity without providing new financial performance data or significant strategic shifts.

Positives

• Conversion of debt into equity can strengthen the balance sheet by reducing liabilities.
• The conversion of the promissory note into preferred stock indicates a step towards equity financing.
• The reporting person, as CEO and Director, is actively involved in the company's financial structure.

Negatives

• The filing does not provide details on the original principal amount of the promissory note or the interest accrued.
• The conversion price of $2.862 per share for the preferred stock may provide insight into the valuation at the time of the note's issuance or conversion.

Risks

• The automatic conversion of Series D-1 Preferred Stock into Common Stock on December 31, 2028, could lead to significant dilution for existing common shareholders if the conversion price is favorable to the preferred holders.
• The terms of the 8% unsecured convertible promissory note suggest a need for capital and potentially a higher cost of debt financing.

Future Outlook

The Series D-1 Convertible Preferred Stock is scheduled to automatically convert into Common Stock on December 31, 2028, unless an earlier conversion occurs. This future conversion event will impact the number of outstanding common shares.

Industry Context

StockSavvy.ai notes that convertible notes and preferred stock are common instruments for early-stage or growth companies to raise capital. The terms of conversion and automatic conversion dates are critical for understanding potential future dilution and valuation.

Stakeholder Impact

• Common shareholders may experience dilution upon the automatic conversion of Series D-1 Preferred Stock into Common Stock on December 31, 2028.
• The conversion of debt to equity could be viewed positively by creditors as it reduces outstanding liabilities.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on December 31, 2028, unless converted earlier.

Key Dates

Keywords

Form 4, SEC Filing, Prov3ctus Biopharma, PVCT, Edward Pershing, Convertible Note, Preferred Stock, Stock Conversion, Beneficial Ownership, Insider Trading